05.18.20

EyePoint Pharmaceuticals Presents Data Showcasing Dexycu at the ASCRS Virtual Meeting

Source: EyePoint Pharmaceuticals

03.02.20

EyePoint Pharmaceuticals Announces Positive Topline 36-Month Follow-up Data for Second Phase 3 Study of Yutiq

Source: EyePoint Pharmaceuticals

01.27.20

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign License Agreement to Develop and Commercialize Dexycu in China, Hong Kong, Macau, and Taiwan

Source: EyePoint Pharmaceuticals

11.14.19

EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

Source: EyePoint Pharmaceuticals

11.04.19

EyePoint Pharmaceuticals Announces Addition of Dexycu and Yutiq to Department of Veteran Affairs Federal Supply Schedule

Source: EyePoint Pharmaceuticals

10.02.19

EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effect

Source: EyePoint Pharmaceuticals

09.27.19

EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meeting

Source: EyePoint Pharmaceuticals

09.09.19

EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meeting

Source: EyePoint Pharmaceuticals

07.25.19

EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code for Yutiq

Source: EyePoint Pharmaceuticals

07.08.19

EyePoint Pharmaceuticals Announces US Commercialization of Dexycu

Source: EyePoint Pharmaceuticals

View more stories